Literature DB >> 17240008

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

S F Little1, B E Ivins, W M Webster, S L W Norris, G P Andrews.   

Abstract

The serological response and efficacy of Bacillus anthracis recombinant protective antigen (rPA) vaccines formulated with aluminum hydroxide adjuvant, either with or without formaldehyde, were evaluated in rabbits. Rabbits that had been injected with a single dose of 25 microg of rPA adsorbed to 500 microg of aluminum in aluminum hydroxide gel (Alhydrogel) had a significantly higher quantitative anti-rPA IgG ELISA titers (p<0.0001) and toxin neutralizing antibody (TNA) assay titers (p<0.0001) than rabbits tested at the next lowest concentration of aluminum (158 microg). Rabbits injected with two doses of 50 microg of rPA formulated with 500 microg of aluminum also had significantly higher serological responses, as measured by a quantitative anti-rPA IgG ELISA (p<0.0001) and TNA assay (p<0.0001), than sera from rabbits injected with a rPA vaccine formulated without adjuvant. Short-term protection against an aerosol spore challenge (448 LD(50)), however, was not significantly different between the two groups (12/12 and 11/12, respectively). Rabbits injected with a single dose of 50 microg of rPA formulated with 500 microg of aluminum and 0.2% formaldehyde had significantly higher ELISA (p<0.0001) and TNA assay (p<0.0001) titers than rabbits that had been injected with a rPA vaccine formulated with adjuvant but without formaldehyde. Short-term protection against a 125 LD(50) parenteral spore challenge, however, was not significantly different between the two groups (14/24 and 9/24, respectively; p=0.2476). Under the conditions tested in the rabbit animal model, significantly higher serological responses were observed in rabbits that had been injected with rPA formulated with aluminum hydroxide gel adjuvant and formaldehyde. However, differences in short-term efficacy were not observed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240008     DOI: 10.1016/j.vaccine.2006.12.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Authors:  Leslie Wagner; Anita Verma; Bruce D Meade; Karine Reiter; David L Narum; Rebecca A Brady; Stephen F Little; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

2.  Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Authors:  James E Galen; Magaly Chinchilla; Marcela F Pasetti; Jin Yuan Wang; Licheng Zhao; Ivonne Arciniega-Martinez; David J Silverman; Myron M Levine
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

3.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

4.  Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.

Authors:  Matthew D Reed; Julie A Wilder; William M Mega; Julie A Hutt; Philip J Kuehl; Michelle W Valderas; Lawrence L Chew; Bertrand C Liang; Charles H Squires
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

5.  Serological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis.

Authors:  Jeong-Hoon Chun; On-Jee Choi; Min-Hee Cho; Kee-Jong Hong; Won Keun Seong; Hee-Bok Oh; Gi-Eun Rhie
Journal:  Osong Public Health Res Perspect       Date:  2012-09

Review 6.  Current Status and Trends in Prophylaxis and Management of Anthrax Disease.

Authors:  Vladimir Savransky; Boris Ionin; Joshua Reece
Journal:  Pathogens       Date:  2020-05-12

7.  Production of polyclonal antibody against kidney antigens: a model for studying autoantibody in feline chronic kidney diseases.

Authors:  Nisakorn Songaksorn; Wilaiwan Petsophonsakul; Kidsadagon Pringproa; Kannika Na Lampang; Nattawooti Sthitmatee; Nuttawan Sriphawattana; Kriangkrai Thongkorn
Journal:  J Vet Sci       Date:  2019-11       Impact factor: 1.672

8.  Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes.

Authors:  Yang Fu; Jie Sun; Shizhen Lian; Xiaoyu Deng; Lei Zhang; Jikai Shao; Hongguang Yu; Xijun Yan; Yanzhu Zhu
Journal:  Front Vet Sci       Date:  2022-02-15

Review 9.  Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation.

Authors:  Paul Löffler
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.